ESTIV Congress 2024 > Sponsors and Exhibitors

Sponsors and Exhibitors

Sponsorship of ESTIV Congress is an excellent way to keep your company’s name out front. We offer Gold, Silver, Bronze, and Exhibitor levels. In addition, you can also choose from a variety of A-La-Carte Sponsorship opportunities, in case you do not wish to exhibit. Why Sponsor?

  • Support the scientists pursuing the NAMs concepts
  • Put your Business in the Spotlight
  • Get your Brand Noticed
  • New Clients, New Customers, New Business
  • Market your Business Inexpensively
  • Develop your Products and Services
  • Find Vendors and Solution Providers

❓ Questions
If you have any queries or if you need further information about the sponsor and exhibitor packages, please contact the congress secretariat via:

Unlike previous ESTIV editions, sponsorship registration is now easily done through an online registration module. The floor plan and information about exhibition centre if available here:


Gold sponsor

Silver sponsors

Bronze sponsors

Exhibitors and supporters


Altertox aims to revolutionize safety testing by making alternative methods to animal testing a reality. To achieve this mission, Altertox has developed a unique strategy to facilitate the implementation of NAMs in business. To equip staff embracing this transition, we designed a unique brainstorming tool, the TATAbox, ensuring a smooth and successful integration of NAMs from the operational to the top management.

Beyond business, universities can leverage the TATAbox to wrap up their educational cycles for bachelor’s and master’s students, providing them with practical knowledge with the latest NAMs techniques.

Our commitment to advancing NAMs is also translated by a deep embedding into the scientific community, collaborating on cutting-edge research projects like PrecisionTOX, ONTOX, PANORAMIX, and ASPIS within the EU’s H2020 program. This, combined with our extensive experience organizing training programs and influencing EU policy, positions Altertox as your ideal partner for a future free from animal testing.

Company page LinkedIn: Altertox
Contact person via LinkedIn: Carme Pizà Juan-Muns

AlveoliX AG

AlveoliX is dedicated to enhancing your laboratory experiments by offering top-notch equipment and consumables for organ-on-chip studies, along with specialized services for comprehensive drug safety and efficacy testing using advanced in-vitro systems.

Our cutting-edge organs-on-chip technology is designed to significantly improve the accuracy of predicting human responses in preclinical drug development, providing invaluable insights into the complexities of human biology.

At the heart of AlveoliX’s mission is the aspiration to establish organs-on-chips as the new standard in preclinical drug development—a progressive and humane alternative to traditional animal experiments. Get in touch with us to learn more about how to apply our transformative approach to advancing drug research and development.

Company page LinkedIn: AlveoliX
Contact person via LinkedIn: Janick Stucki

BiomimX srl

BiomimX S.r.l. is a pioneer in Organ on a Chip (OoC) technology, producing the next generation of clinically relevant in-vitro models for pharmaceutical drug discovery and testing. Its proprietary platform integrates microfluidics, 3D cell culture, live human cells, and mechanical stimuli to produce “Beating OoC” . These recapitulate, with unprecedented precision and predictability, clinically relevant models reflective of human physiology and pathophysiology. Pharma R&D is an area where animal models continue to fall short due to lack of translatability and/or lack of relevant models. Regulatory agencies in the US and Europe are now moving forward to encourage biopharma’s use of more predictive non-animal models. BiomimX is poised to be a leader in this space and has gained early traction with industry.

The advantage of BiomimX approach is its patented uBeat platform which provides 3D microtissues with controlled mechanical stimulation that revolutionizes how new drugs are tested for safety and efficacy, offering advantages over the current 2D models.

BiomimX lead model is uHeart (Visone, Tox Sciences, 2023; +4 additional cardiac publications), a functional beating heart on a chip for cardiotoxicity and safety testing early in the pipeline. uHeart was recently qualified with 12 drugs as a predictor of functional cardiotoxicity, showing 83.3% sensitivity, 100% specificity, and 91.6% accuracy. Our pipeline includes a range of predictive physiological and pathophysiology models. uKnee (osteoarthritis; Occhetta, Nature Biomed Eng, 2019), uScar (fibrosis; Visone, Adv Health Mat, 2023), uGut (Ballerini, Nature Biomed Eng, under review), uLung and uLiver-Heart (Ferrari, Adv Mat Tech, 2023).

BiomimX founders, with expertise in microfluidics, microtechnology, and advanced 3D in-vitro cell culture, serve in academia and have notable leadership roles in key societies such as the European Organ on Chip Society. They are in communication with the EMA regarding BiomimX models and have a strong publication record and EU grant success in advancing the field of OoC. BiomimX offers advanced in vitro human models as visionary tools to reduce animal testing in preclinical development, aligning with the 3R principle and encouraging the adoption of alternative methods in drug testing.

Company page LinkedIn:  BiomimX® Srl
Contact person via LinkedIn: Erika Ferrari


cellQART made by SABEU

IN STOCK! cellQART® Cell Culture Inserts – Direct from the original manufacturer. Meet us in person at the ESTIV 2024. With our brand of cellQART®, we make the highest quality Cell Culture Inserts available at affordable prices. We offer a wide portfolio of Cell Culture Inserts in diverse pore sizes, membrane optics, individually packed and pre-loaded cellQART® Well Plates. Our product portfolio comes with PET membranes in translucent, clear extended culture or clear optics in 6-, 12- and 24-Well format. The Inserts are tissue culture treated, sterile, RNase / DNase free and non-pyrogenic.

We work with industry leading quality standards to ensure 100% membrane parameter consistency and reproducible cell culture results. We are beyond excited to be part of the 3Rs transformation. For more information, visit our webshop and contact us on! Follow us on Twitter, LinkedIn and YouTube or Instagram.

Company page LinkedIn:  cellQART ®
Contact person via LinkedIn: Karina Cuanalo-Contreras

CN Bio

CN Bio, a leading organ-on-a-chip (OOC) company, offers solutions to improve the accuracy and efficiency of preclinical drug discovery. Our PhysioMimix® suite of microphysiological systems, 3D-validated cells, consumable plates, and Contract Research Services facilitate the prediction of human responses to drug exposure, in the presence or absence of disease, so new medicines can be brought to market rapidly and cost-effectively. Utilizing primary human cells, our perfused 3D liver-on-a-chip recapitulates the organ’s microarchitecture, environment and function in vitro. It provides a viable alternative to animal models where translatability to humans is poor and for testing advanced drug modalities that require human-specific targets. The model used in our drug-induced liver injury (DILI) assay generates physiologically relevant, translatable, mechanistic toxicity data that facilitates the progress of the safest drugs into in vivo studies or provides insights for human clinical trials.

Company page LinkedIn:  CN Bio
Contact person via LinkedIn: Ciara McGahey


Creatio is a benchmark academic Production and Validation center of Advanced Therapies of the University of Barcelona accredited by the AEMPs to produce Advanced Therapy Medicinal Products (ATMPs). It is a technological developer center with TECNIO accreditation that bridges the gap between research and the clinic promoting innovation.

Creatio has the commitment to offer support and solutions based on Advanced Therapies to increase the efficiency of the healthcare system and improve the quality of life of society.

At Creatio we offer a tailored support along the entire product development with our four areas: basic and translational research, preclinical studies, clinical production, and management, and skilled and experienced professionals.

The basic and translational research area is dedicated to conducting state of art research on advanced therapies for the treatment of neurological diseases. We have various models and techniques available to test your products and validate your research hypotheses.

The preclinical studies area is dedicated to the validation of new technologies and healthcare products under development. We offer a wide range of preclinical studies conducted under high quality standards, ISO 9001:2015 and/or GLP quality standards, as well as technical and scientific advisory services.

The clinical production area is dedicated to the production of ATMPs of cell, gene and tissue engineering, for clinical use. Clinical production follows high quality standards, ISO 9001:2015 and/or good manufacturing standards (GMP)..

The managing area is the backbone of Creatio, responsible for managing and promoting all activities, establishing strategic alliances, and identifying collaborative opportunities and projects.

All our work is carried out to the highest quality standards: ISO 9001:2015, GLP and GMP.

Creatio encourages the establishment of strategic alliances with all the stakeholders of the healthcare ecosystem to promote the development of innovative technologies and therapies for the wellbeing of society.

Company page LinkedIn:  Creatio UB
Contact person via LinkedIn: Andrea Comella Bolla


Epithelix is Biotech Company, specialized in tissue engineering, leader for in vitro assessment of drug efficacy and toxicity on human respiratory tract. We provides in vitro alternatives to animal testing (NAMs).

Epithelix has developed a unique technology for long-term culture of fully primary in vitro human reconstituted tissues. The company commercialize ready-to-use nasal, tracheal, bronchi (MucilAir™), small-airways (SmallAir™) and alveolar (AlveolAir™) epithelia and advanced immunocompetent models integrating macrophages, neutrophils or dendritic cells.

Epithelix also provide testing services (CRO activity) offering a panel of assays to study airway pathologies like Asthma, Cystic Fibrosis and Chronic Obstructive Pulmonary Diseases, Viral and Bacterial infections. A wide range of applications are available: toxicity assays, disease modelling, permeability of inhaled drugs, efficacy testing of novel antiviral or antimicrobial therapy, etc

Company page LinkedIn: Epithelix
Contact person via LinkedIn: Xiao-Yann Huang


EPISKIN, world leader in tissue engineering, offers Human Reconstructed Tissues to the global scientific community – academic and industry – to support research and development activities in Safety and Efficacy.

Based in Lyon, France, we partner with cosmetical, pharmaceutical and chemical industries worldwide to develop relevant and reliable safety and efficacy tests. Our models are critical tools to speed up Research and Development phases and to shorten the time to market. Some screening tests are already referenced and validated as alternatives to animal use, and others are in the process of validation.

Our unique cell culture process allows to industrialize important volumes of in vitro models of reconstructed human tissues with well characterized histology, functionality and ultrastructure features. The production unit has been designed to deliver every week our clients with thousands of human tissues.

Our product lines include: Reconstructed human epidermis, Full Thickness Model, Reconstructed Human Corneal, Oral, Gingival, and Vaginal Epithelia

All of these models allow the evaluation of raw materials, active ingredients and finished products being either in a solid, liquid, powder, cream or gel form.

Our mission are to develop and produce robust and valuable reproducible models, ensure trainings and education on how to use our models as alternative methods to animal testing and support our customers and partners in providing a dedicated and customized service

Company page LinkedIn:  EPISKIN SA
Contact person via LinkedIn: Christelle Videau

European Research Biological Center (ERBC)

European Research Biological Center (ERBC) is a 50 years’ leading CRO committed to bridge the gap between preclinical and clinical research by better predicting the efficacy and safety of new compounds.

Offering a comprehensive range of experimental capabilities, preclinical models, regulatory pre-IND package and consultancy services, ERBC allows biopharmaceutical and chemical industry professionals to de-risk innovation and enhance R&D productivity.

With highly qualified teams in France and Italy, ERBC is offering a customer-centric approach while committed in improving all aspects of study design and conduct applying alternatives to animal testing as a priority.

Company page LinkedIn: ERBC (European Research Biology Center)
Contact person via LinkedIn: will be available soon. 


More information will be available soon. 

Company page LinkedIn: Gentronix Limited
Contact person via LinkedIn: Gentronix Limited

HiLung Inc.

Based on proprietary hiPSC engineering and semi-automated manufacturing, our robust and durable alveolar (HiAlv) and airway (HiTrach) cell plates, as well as 3D organoids and disease models, offer consistency, durability and clarity (devoid of injury upon sourcing), thus reproducibility and human-relevance – decisive and efficient when gaining species- and organ-dependent insights in search of human toxicity and pandemic preparedness, not to mention respiratory therapeutic efficacy.

Company page LinkedIn: HiLung Inc.
Contact person via LinkedIn: will be available soon. 


More information will be available soon. 

Company page LinkedIn: ImmuONE
Contact person via LinkedIn: Louis Scott


IIVS is a GLP-compliant Contract Research Organization focused on non-animal alternatives to toxicology and product safety testing.  We work with industry (including chemical, pharmaceutical, cosmetic and personal care companies) as well as academic and government organizations, performing testing services in non-animal models. In addition, IIVS assists in the validation of New Approach Methodologies (NAMs) to traditional assays. As a non-profit entity, our laboratory activities and contributions fund our Education and Outreach programs, providing extensive training and active involvement in the advocacy and promotion of non-animal methods worldwide. For more information, visit

Company LinkedIn:  Institute for In Vitro Sciences, Inc.
Contact person via LinkedIn: Brent Gilbert

International Collaboration on Cosmetics Safety (ICCS)

The International Collaboration on Cosmetics Safety (ICCS) is a global initiative focused on advancing the adoption of animal-free assessments of cosmetics, and their ingredients, for human health and environmental safety. ICCS brings together scientists and experts from cosmetics manufacturers and suppliers, industry and research associations, and animal protection organizations to drive greater global awareness and confidence in animal-free science through research, education, and regulatory engagement.

Company page LinkedIn:  International Collaboration on Cosmetics Safety
Contact person via LinkedIn: Kelly Semrau


INVITROLIZE offers safety assessments for inhalable materials.

We help you to identify respiratory irritants and sensitizers early in product development.

Get peace of mind with our award-winning patented technology. Our human cell-based in vitro model allows for the first time the identification and differentiation of respiratory sensitizers and respiratory irritants under air-liquid interphase realistic exposure conditions.

Company page LinkedIn: invitrolize
Contact person via LinkedIn: Arno Gutleb

IVTech srl

IVTech is an Italian biotech company, founded in January 2014 by 4 bioengineers. We started as a spin-off of the University of Pisa. Now we are PMI, providing our technology and services to clients, involved in the biological research field. Our mission is to provide technology and services to fill the lack between a 3D and static in-vitro model and a 5D in-vitro model, highly representative of the human reality. The 5D concept means a three-dimensional model (I-IIIrd degree of complexity), based on cells or ex-vivo explants, immersed in a dynamic environment (IVth degree of complexity), which recreates the native stimuli and exposed to a cross communication with other tissues (Vth dimension). IVTech offers: 1. A fluidic platform to overcome the limitation of the obsolete in-vitro technology. The use of our systems permits the study of a complex biological scenario, characterized by a dynamic environment, a cross modulation between different tissues, and a stimulation pathway, mimicking even a disease condition. 2. Engineering service in the design of an advanced in-vitro model. We strongly think that the development of a 5D in-vitro model is a multidisciplinary matter. Therefore, we help our customer, basing on our engineering background. We develop computational models and mathematical models to scale down the physiological dimensions to the in-vitro scenario, increasing the correlation with the reality. 3. Biological service. We offer the opportunity to test drug compound or a new material, basing on our biological model. This service is developed in collaboration with our partners. “All our efforts are focused on the design and development of next generation products to push towards ever better in-vitro models of integrative human patho-physiology”

Company page LinkedIn: IVTech
Contact person via LinkedIn: Tommaso Sbrana

Japan Tissue Engineering Co., Ltd.

J-TEC supports a variety of in vitro testing for the animal alternatives by providing reconstructed living human 3-D tissue products, LabCyte. Our technologies are backed by the reliable tissue engineering techniques developed in manufacturing regenerative medicine products for decades. LabCyte have a structure and morphology that parallels those of human tissues, which support researchers to perform experiments in highly physiological conditions.

J-TEC offers two LabCyte product lines: EPI-MODEL (reconstructed human epidermis, listed in OECD TG431 and TG439) and CORNEA-MODEL (reconstructed human corneal epithelium, listed in OECD TG492). The recent release of the draft OECD TG442D, in vitro skin sensitization test EpiSensA which uses LabCyte EPI-MODEL, has expanded the applicability of LabCyte models in safety testing.

Company page LinkedIn: LabCyte by J-TEC
Contact person via LinkedIn: Hiromichi Mitake

LifeNet Health LifeSciences

LifeNet Health LifeSciences gives healing every advantage by providing research solutions that empower groundbreaking discoveries around the world. Our goal is to improve health and safety for humankind by providing all-human cells, in vitro physiological systems, biospecimens for research, and cytotoxicity services. We support scientists in the pharmaceutical, biotech, agriscience, food safety, and cosmetic industries.

Company page LinkedIn: LifeNet Health LifeSciences
Contact person via LinkedIn: Stacey Hanson


Locsense develops and supplies in-vitro sensing equipment. Our flagship device, the Locsense Artemis, is a non-invasive sensor that monitors cell health, and barrier integrity, enabling groundbreaking discoveries in fields like cosmetics, pharmaceuticals and the food industry.

Locsense is at the forefront of lab technology with devices that non-invasively monitor and test cells outside the body. In our bodies, cells often form protective barriers. Think of these barriers as tiny walls that separate different areas. For example, the lining of your gut has cells that create a barrier between your food and the rest of your body, or the skin which forms a protective barrier for influences from outside.

Impedance measurements offer a way to measure how strong these barriers are and whether they are intact. The Artemis offers insight into how healthy cell barriers are. This is crucial for drug testing, studying diseases, and making sure our body’s defenses work properly.

Our products are designed to combine with conventional workflow. At the same time they can be coupled to innovative in-vitro cell culture platforms, such as microfluidic chips, organs-on-chip or smartplates.

Company page LinkedIn: Locsense
Contact person via LinkedIn: Susan Roelofs

L’Oreal Research & Innovation

At L’Oréal, we are committed for beauty with no animal testing.

L’Oréal Groupe continuously invests in the development of non-animal testing methods and rallies the scientific communities in this journey. We share our scientific advances, knowledge and expertise to foster the use of non-animal testing methods, while engaging with regulators and decision makers to cease animal testing for cosmetics everywhere in the world.

Click here for more information:

Company page LinkedIn:  L’Oréal
Contact person via LinkedIn: Emilie Planel

Mattek In Vitro Life Science Laboratories s.r.o.

MatTek is at the forefront of tissue engineering and is a world leader in the production of in vitro 3D reconstructed human tissue models for regulatory toxicology. Our skin, ocular, mucosal, and respiratory tissue models address toxicology and efficacy concerns throughout the cosmetics, chemical, pharmaceutical, and household product industries.

The outstanding reproducibility and high relevance of MatTek’s human cell-derived 3D tissue models provided impressive results in many international multi-laboratory validation studies. Our EpiDerm and EpiOcular models are validated by the OECD as an alternative to animal testing. At the moment, MatTek Corporation offers commercially 15 reconstructed human tissue models, animal models, and “beta” models of the colon, kidney, and liver.  

In 2009, the subsidiary of MatTek Corporation, with the business name MatTek In Vitro Life Sciences Laboratories s.r.o. (IVLSL) was established in Slovakia, Bratislava. In 2012, the commercial production of the EpiDerm tissue model in MatTek IVLSL started, and the production of the EpiOcular tissue model followed in 2013. At the moment EpiDerm, EpiDerm Full-Thickness, EpiOcular, EpiIntestinal, EpiAirway, EpiOral, EpiGingival, and MelanoDerm are available from the EU. 

Extension of production capabilities in Europe enabled MatTek partners better accessibility to products in a shorter time and eliminated administrative processes related to customs clearance. We also offer free of charge training in our laboratories in Bratislava. Training is always personalized and number of participants is 3 persons. During one training week, attendees can be trained for 3 assays. After training, the certificates of training are issued for each person.

The core business of our company is the research and development of new tissue models and methods, which allow us to reduce or replace using of animals in laboratory tests for chemicals, cosmetics, pharmaceuticals, household products, pesticides, medical devices, etc. MatTek IVLS is, therefore, a member of many scientific societies, organizations such as SETOX (Slovak Toxicology Society), ESTIV (European Society of Toxicology In Vitro), EUSAAT (European Society For Alternatives To Animal Testing), CELLTOX (Associazione Italiana Tossicologia In Vitro), Adebiotech France.

Company page LinkedIn: MatTek Life Sciences
Contact person via LinkedIn: Miroslav Kandar


NETRI, an industrial start-up, offers healthcare industries the ability to generate mini human organs on chip which, coupled with AI treatments, can predict the clinical effect of a drug candidate. NETRI offers its customers support throughout the development of their drug or product candidate, providing predictive answers on toxicity, efficacy and modes of action in the discovery, preclinical and clinical phases. Organ-on-a-chip devices enable the creation of healthy or pathological physiological models. Using its high-throughput microfluidic technologies, NETRI’s models recreate human physiology in vitro by co-culturing cells, either primary or derived from human stem cells, compartmentalized and coupled with functional activity measurements. NETRI today markets its NeuroFludidics™ organ-on-a-chip models in pain, cosmetics and nutritional health applications.

Company page LinkedIn: NETRI
Contact person via LinkedIn: Thibault Honegger

Newcells Biotech

Newcells Biotech provides clients with validated in vitro tools to understand how drugs interact with tissues. We build functional in vitro models of the kidney, retina and lung to improve clinical translation and drug discovery. By applying our expertise in induced pluripotent stem cells (iPSCs), primary tissues, a deep understanding of cellular physiology and organoid technology, we have built validated models and assays that have proven to be predictive of how drugs interact with tissues and organs.

Company page LinkedIn: Newcells Biotech Ltd
Contact person via LinkedIn: Jenny Cheung

Nikon Europe B.V.

The Nikon BioImaging Lab (NBIL) is a Contract Research Organization (CRO) that provides microscope-based imaging and analysis services to the biotech, pharma, and larger research communities, offering contract research services from the company that knows imaging.

The NBIL provides:


    • Imaging Services – A diverse range of samples can be imaged, from plates to histology slides (2D and 3D; live or fixed specimens). This includes time-lapse imaging of dynamic cellular processes, along with high-content image acquisition capabilities.
    • Analysis – Nikon’s AI-powered analysis software enables automation and standardization in data generation and offers a higher and more refined data yield than standard microscopy services.
    • Experimental Design – Expertise in assay development and execution as well as project consulting with the NBIL’s team of biologists and microscopy imaging professionals.


At the Nikon BioImaging Lab (NBIL), we are passionate about helping you get insights by providing solutions to your microscope-based imaging needs. We offer services for both imaging and analysis to organizations in biotech, pharma, and larger research communities that trust us with their projects.

Our center, the first in Europe, hosts Nikon’s unique cutting-edge microscopy instrumentation and software. NBIL’s full-service capabilities also include access to expert biologists and microscopists, who are available to provide quality cell and tissue culture, data acquisition, analysis, and reporting.

At the Nikon BioImaging Lab, we have a team of highly experienced scientists ready to turn your vision into quantitative data. We have experience ranging from single molecule assays, cell culture in 2D and 3D, organoids and spheroids, to complex thick tissues, as well as MPS (organ-on-a-chip microphysiological systems). With all of our expertise, we are confident that Nikon is the ideal imaging partner to support your research.

Company page LinkedIn: Nikon Biolmaging Lab
Contact person via LinkedIn: Andreas Kompatscher

PELOBiotech GmbH

PELOBIOTECH GmbH is a supplier of reagents for biomedical research. With a focus on primary cell culture, we distribute one of the broadest portfolios from our exclusive partners all over the world. Our portfolio currently offers 5,000+ products in the field of human &animal primary cells, adult stem & iPS cells, media & tools. PELOBiotech offers modified and tagged primary & stem Cells, diseased cells and 2D&3D cell culture systems. We provide customized solutions with a choice of prime media in R&D, GMP-like and GMP quality, as well as xeno-free, serum-free and defined solutions.


PELOBiotech GmbH More than Competence4Cells

Company page LinkedIn: PeloBiotech GmbH
Contact person via LinkedIn: Cassandra Deichsel

PETA Science Consortium International e.V.

PETA Science Consortium International e.V. advances the development, use, and global regulatory acceptance of reliable and relevant non-animal testing methods that protect human health and the environment. It does so by designing and funding experiments to build confidence in non-animal toxicity testing, conducting retrospective data analyses, donating in vitro human tissue models and equipment to researchers, and leading efforts to standardise in vitro testing protocols. The Science Consortium strives to ensures that information regarding the use of non-animal tests is accessible to all by hosting free webinars and workshops, publishing articles in peer-reviewed journals, and presenting its work at scientific conferences. It also develops informative factsheets, organises free training opportunities for scientists, and provides travel awards for early-career scientists to attend workshops. More information about PETA Science Consortium International e.V. can be found at

Company page LinkedIn: PETA Science Consortium International e.V.
Contact person via LinkedIn: Andreas Stucki

Primacyt Cell Culture Technology GmbH

PRIMACYT is a German biotechnology company and GLP certified contract researcher. We offer one of the world’s most comprehensive portfolios of liver related products obtained from human and animal species including non-human primates, dogs, birds, fresh and seawater fish, rodents, and farm animals. Our product portfolio includes fresh and cryopreserved primary human and animal cells, liver subcellular fractions, ex vivo human skin explants, full thickness and dermatomed skin discs, blood derived products, and consumables for applications in environmental toxicology, preclinical drug testing and product development in human and animal health. Products are manufactured in accordance with OECD test guidelines when applicable.

We have a validated technology platform to assay drug transporter activities in stably transfected HEK293-cells and primary hepatocytes. We are GLP certified and serve as a reference laboratory for the EU.

Company page LinkedIn: PRIMACYT Cell Culture Technology GmbH
Contact person via LinkedIn: Dieter Runge


ProtoQSAR – MolDrug is a Spanish SME with 10 years of experience, specializing in computational toxicology and the design and development of drugs and other chemical substances. Our expertise extends to compound design, optimization, valorization, and development, across small molecules, peptides, nanomaterials, and mixtures. We also offer services in drug reprofiling and virtual screening, with a strong focus on the latest AI-powered chemoinformatics and structural bioinformatics tools, including QSAR models, molecular docking, pharmacophore modeling, homology modeling, molecular dynamics, and molecular mechanics analyses.

Our work spans multiple sectors including biotech, pharma, veterinary, cosmetics, nutraceuticals, materials, and agrifood, with a specialized focus on chemistry and (computational and regulatory) toxicology. This includes comprehensive toxicology services, crucial for advancing safer chemical and drug development with minimal impact on human and environmental safety.

We have participated in over 10 international research projects, such as the HORIZON projects “ONTOX” (and ASPIS cluster), BIO-SUSHY, CheMatSustain, HYPIEND, among 20+ others. Our team has published over 80 articles in relevant fields.

Our research and service pipeline covers all phases of drug and compound development, with a significant portion dedicated to computational and regulatory toxicology:

  • Target discovery: Including differential gene expression analysis, homology modeling, and pathway analysis.
  • Hit to lead: We provide virtual screening, pharmacophore modeling, and QSAR models focused on compound safety (toxicity and ecotoxicity) and bioactivity.
  • Lead optimization: Emphasizing refined docking and molecular dynamics with ADME & toxicity predictions.
  • Regulatory-related services: Including ADME & toxicity QSAR models and comprehensive regulatory consultancy to navigate complex compliance landscapes.

Our QSAR models are particularly suited for predicting and assessing (eco)toxicological and other properties, offering:

  • Fast, resource-efficient results,
  • Regulatory validity backed by automated QMRF and QPRF reporting,
  • A commitment to reducing animal testing through in silico methodologies.

These models, part of ProtoPRED, the largest QSAR platform available for REACH compliance, can be explored further, including a fully-fedged free trial, at

Company page LinkedIn:  ProtoQSAR
Contact person via LinkedIn: Simon Perera

SenzaGen AB

SenzaGen is dedicated to advancing in vitro science and testing, driving the transition from animal testing to methods that better reflects human biology. The Group offers state-of-the-art non-animal tests and tailored consulting services. Utilizing our unique GARD® technology, which combines genomic data from human cells with machine learning, we possess a distinct capability to identify and analyze whether a chemical could cause allergic reactions on the skin or in the respiratory tract. With demonstrated applicability for both pure chemicals and mixtures, GARD®skin (OECD TG442E) meets the needs of multiple industries, bringing new opportunities to the field of in vitro skin sensitization testing.

Company page LinkedIn:  SenzaGen
Contact person via LinkedIn:  Tina Lawesson

TEAM mastery S.r.l.

More information will be available soon. 

Company page LinkedIn: TEAM mastery s.r.l.
Contact person via LinkedIn: Sofia Gallicchio

Unilever Global IP Limited

Unilever manufactures a range of home, personal care, beauty & wellbeing, and food products that are sold throughout the world in over 190 countries, with over 400 brand names.  On any given day, 3.4 billion consumers use Unilever products sold under many well-known brands, including Dove, AXE, Lifebuoy, Comfort, Sunlight, and Knorr.

Safety and Environmental Assurance Centre (SEAC) is a key part of Unilever R&D with responsibility for ensuring that Unilever’s innovations are designed to be safe and sustainable.  Our leading-edge approach to assuring the safety of Unilever’s products for people and the planet has one clear purpose: to guarantee that our products are safe, without the need for animal testing. That’s why we say #UseScienceNotAnimals.

Our ability to innovate using non-animal safety assessment approaches is underpinned by scientific partnerships with over 70 leading research teams globally to develop and apply new capability. We look to openly share the experience gained from these collaborations through publications, presentations and through our website:

Company page LinkedIn: Unilever
Contact person via LinkedIn: Carl Westmoreland


VITROCELL® is specialized in the development of advanced in vitro exposure systems for inhalation toxicology: mammalian cells can be exposed to gases, environmental atmospheres, nano particles and complex mixtures at the air/liquid interface. VITROCELL® Skin modules and autosamplers are designed for the exposure of tissue. Our customers are leading research institutes, contract research organizations, regulatory authorities as well as the pharmaceutical and other industries throughout the world.

Company page LinkedIn: Vitrocell Systems GmbH
Contact person via LinkedIn: Melanie Bucher

Xenometrix AG

Xenometrix develops and manufactures ready to use, quality-controlled assay kits for the genotoxicity assessment of chemicals, pharmaceuticals, or biologicals, for the detection of endocrine active compounds as well as ex vivo explants for in vitro skin permeation testing:

Ames Test Kits in agar plate format with Petri dishes (MacroAmes1 in line with OECD 471) or in 6 well plate format (MicroAmes6). The microplate fluctuation assay format (Ames MPF in line with ICH M7 guideline) allows automation, has a low consumption of test compound, 11x less consumption of S9 (in line with 3Rs and less test animals) and produces significantly less plastic waste.

Rapid Micronucleus MoA Test kit offers a fast and clear detection of chromosomal aberrations like micronuclei, N-Buds, bridges with pancentromeric probes and enables a clear identification of clastogenic compounds (OECD 483, 473).

Ready to use test kits for the detection of compounds with agonistic and antagonistic endocrine activity, towards estrogen and androgen receptors.

Also available from Xenometrix are ex vivo human and porcine skin explants for the in vitro permeation testing of chemicals, skin penetration, biodistribution (OECD 428, MDR 2017/745).


Together with its partners Xenometrix offers analytical services under GLP and non GLP condition: Ames Test for screening, for the detection of impurities, for mixtures or for OECD TG471, in vitro micronucleus (TG483), chromosomal aberration (TG471), screening for estrogen and androgen active compounds, in vitro permeation testing, for registration purposes of (agro)chemicals, biocides, pharmaceuticals, cosmetics, substance-based medical devices.

Company page LinkedIn: XENOMETRIX
Contact person via LinkedIn: Csaba Boglári


4Dcell is a biotechnology company with experience in creating and commercializing advanced 2D and 3D microphysiological systems, ideally suited for drug development applications. The company pioneered the “Organ-in-a-well” concept through the introduction of 3 groundbreaking technologies: Micropatterned plates, SmartSphero Plates and SmartHeart Plates. These innovations set new industry standards by offering unprecedented ease of use for high throughput screening and data collection from 3D models. Providing consumables or offering services in our biofacilities, these models find wide-ranging toxicological applications in various fields such as cardiology, immunology, oncology, hepatology, and neurology.

Company page LinkedIn: 4Dcell
Contact person via LinkedIn: Cyril Cerveau